Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

#What is the Anticipated CAGR of the Oncolytic Adenovirus Market, and What Factors Will Drive It?#_x000D_

In recent years, there has been substantial growth in the oncolytic adenovirus market. The market size is projected to escalate from $122.31 billion in 2024 to $132.87 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 8.6%. Factors contributing to the growth during the historic period include an upsurge in cancer cases, an increased demand for specialized cancer treatments, a surge in R&D funding, enhancement in delivery techniques, and regulatory authorizations._x000D_

_x000D_

There is an anticipated robust expansion in the oncolytic adenovirus market in the upcoming years. This market is predicted to reach $183.22 billion by 2029, recording a compound annual growth rate (CAGR) of 8.4%. The impending growth in the forecasted period can be credited to factors such as the rising prevalence and incidence of cancer, the broadening scope of combination therapies, enhancements in regulatory processes and approvals, evolving innovations in virus engineering, and an increase in funding for oncology research. Key trends throughout this period encompass progress in viral engineering techniques, improved drug delivery systems, precision advancements in tumor targeting, enhanced combinations for immunotherapy, and developments in patient monitoring and diagnostics._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp_x000D_

_x000D_

#What are the Fundamental Drivers and Innovations Shaping the Oncolytic Adenovirus Market?#_x000D_

The escalating cases of cancer are predicted to fuel the expansion of the oncolytic adenovirus market. Characterized by rampant cell growth and its spread to other body parts, cancer’s rising occurrence is influenced by factors such as aging populations, lifestyle habits, environmental factors, genetic susceptibility, and more effective detection methods. Oncolytic adenovirus, which targets and destroys cancer cells selectively, provides a hopeful strategy for addressing the growing prevalence of cancer. For example, in May 2024, the National Cancer Institute (NCI), a US governmental body, released reports indicating nearly 20 million new cancer cases and 9.7 million deaths globally. These figures are expected to climb to 29.9 million cases and 15.3 million deaths by 2040. Furthermore, data from the Australian Bureau of Statistics, an Australia governmental agency, disclosed that 1.8% of Australians were diagnosed with cancer in 2023. The disease affected males (2.1%) more than females (1.6%), particularly in the age group of 75 and above. As a result, the upsurge in cancer cases is propelling growth in the oncolytic adenovirus market._x000D_

_x000D_

#How Is the Oncolytic Adenovirus Market Segmented?#_x000D_

The oncolytic adenovirus market covered in this report is segmented –_x000D_

_x000D_

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types_x000D_

2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications_x000D_

3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes_x000D_

_x000D_

Subsegments:_x000D_

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based, Second-generation Adenovirus Type 5-based, Engineered Adenovirus Type 5-based_x000D_

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based, Second-generation Adenovirus Type 2-based, Engineered Adenovirus Type 2-based_x000D_

3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Oncolytic Adenovirus Market Growth?#_x000D_

North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Trends Are Shaping the Future of the Oncolytic Adenovirus Market?#_x000D_

Key players in the oncolytic adenovirus market are directing their efforts towards combination therapies such as VCN-01. This therapy fuses oncolytic virotherapy with chemotherapy with the goal of heightening tumor targeting and augmenting therapeutic results. VCN-01 is a specially engineered oncolytic adenovirus which is designed to selectively infiltrate and decimate cancer cells while simultaneously increasing the potency of chemotherapy. For instance, in May 2024, Theriva Biologics, a clinical-stage immuno-oncology company situated in the U.S., declared that the U.S. Food and Drug Administration (FDA) has conferred Fast Track Designation (FTD) on its premier candidate, VCN-01. This designation is pertinent to VCN-01 when used concomitantly with gemcitabine and nab-paclitaxel in the curative regimen of metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that aims and proliferates within tumor cells, contributing to the disintegration of the tumor stroma, a significant barrier to effective cancer management._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report_x000D_

_x000D_

#How Is the Oncolytic Adenovirus Market Defined and What Are Its Core Parameters?#_x000D_

Oncolytic adenovirus is a genetically modified virus designed to selectively infect and destroy cancer cells while sparing healthy tissue. It replicates within tumor cells, causing them to rupture and release new viral particles, which further attack the cancer. Additionally, it stimulates the immune system to enhance the body’s anti-tumor response._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21235_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model